https://www.selleckchem.com/products/Y-27632.html
Our paper differs from previous literature in two ways 1.We think in terms of clinical consequences, what benefits patients, what harms patients. Our main message is using a not logic-respecting efficacy measure can potentially harm patients in a randomized controlled trial (RCT), as we prove analytically, and demonstrate with the OAK blood-based tumor mutational burden (bTM study. 2.We follow nature, which mixes effects within each treatment arm. Our secondary message is that following nature to mix within each treatment arm first be
Like
Comment
Share
